Skyrizi

Skyrizi®

Skyrizi® (risankizumab-rzaa) is an intravenous infusion given every 4 weeks x 3 doses indicated for the treatment of moderately to severely active Crohn’s disease.

For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.

Skyrizi® Referral Form

MANUFACTURER:

AbbVie Inc.

CLASS:
Monoclonal Antibody
WHAT IT TREATS:
PRESCRIBED BY:

Various

HOW ADMINISTERED:
IV Infusion
FREQUENCY:

Week 0, week 4, then every 12 weeks thereafter

Length of infusion:
60 mins